JB Capital LLC Purchases 5,484 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

JB Capital LLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 16.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 39,213 shares of the medical device company’s stock after buying an additional 5,484 shares during the quarter. JB Capital LLC’s holdings in Tandem Diabetes Care were worth $1,412,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Brooklyn Investment Group acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter worth $28,000. Assetmark Inc. acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $29,000. ORG Wealth Partners LLC acquired a new position in Tandem Diabetes Care during the 3rd quarter worth approximately $30,000. Waldron Private Wealth LLC bought a new position in Tandem Diabetes Care in the 3rd quarter valued at approximately $50,000. Finally, McIlrath & Eck LLC bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $52,000.

Analyst Upgrades and Downgrades

TNDM has been the subject of a number of research reports. Sanford C. Bernstein assumed coverage on Tandem Diabetes Care in a research note on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 price target for the company. Morgan Stanley raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price on the stock in a report on Monday, December 2nd. Canaccord Genuity Group lowered their target price on Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Robert W. Baird reduced their price target on Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating on the stock in a research report on Thursday, November 7th. Finally, Barclays lifted their price objective on Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Price Performance

Shares of TNDM opened at $37.06 on Monday. The stock has a market cap of $2.43 billion, a P/E ratio of -19.20 and a beta of 1.32. The business’s fifty day moving average is $34.85 and its 200 day moving average is $37.37. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. Tandem Diabetes Care, Inc. has a 12-month low of $21.85 and a 12-month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. The company had revenue of $243.97 million during the quarter, compared to the consensus estimate of $224.14 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm’s revenue for the quarter was up 31.4% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.38) earnings per share. Sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the director now directly owns 195,190 shares of the company’s stock, valued at approximately $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.20% of the stock is currently owned by insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.